Leading market players are investing heavily in research and development to expand their product lines, which will help the Recombinant Proteins market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Recombinant Proteins industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Recombinant protein industry to benefit clients and increase the market sector. In recent years, the Recombinant Proteins industry has offered some of the most significant advantages to the fields of medicine, biotechnology and pharmaceuticals. Major players in the Recombinant Proteins Market, including Abbvie Inc., Amgen Inc., Bio-Rad Laboratories Inc., Eli Lilly and Company, Merck KGaA, Novo Nordisk AS, Sanofi SA, Thermo Fisher Scientific Inc., Novartis AG, GlaxoSmithKline PLC are attempting to increase market demand by investing in research and development operations.
Merck KGaA, a subsidiary of E. Merck KG, operates as a science and technology company. Its activities encompass the discovery, development and manufacturing of prescription drugs targeting cancer, multiple sclerosis and infertility. Additionally, Merck is involved in the development of various materials, such as liquid crystal mixtures and organic light-emitting diode (OLED) materials, as well as cosmetic active ingredients and pigments for coatings.
Moreover, the company offers a diverse range of products, including lab water systems, gene editing tools, cell lines, antibodies, microbiology and biomonitoring products, along with test assays, analytical reagents and flow cytometry kits and instruments, providing comprehensive solutions across various sectors including healthcare, performance materials and life sciences. With a presence spanning Europe, North America, Asia-Pacific, Latin America and the Middle East and Africa, Merck is headquartered in Darmstadt, Hesse, Germany. In February 2020, Merck KGaA (Germany) collaborated with Donghao Lansheng (Group) Co., Ltd. on a project based in China.
This partnership aimed to evaluate a new import policy in China, which is intended to streamline the clearance process for research items used in biomedical innovation and analytical purposes via customs, facilitating Merck's operations in the country.
Thermo Fisher Scientific Inc. (Thermo Fisher) is a leading provider of medical equipment, analytical instruments, reagents, consumables, software and services designed to address complex analytical challenges across various fields, including research, diagnostics and clinical laboratories. The company offers comprehensive solutions for cellular analysis, biology, flow cytometry and synthetic biology. Its product portfolio encompasses technologies for mass spectrometry, genetic sequencing, electron microscopy, as well as protein and molecular biology research.
Thermo Fisher serves a diverse customer base, including pharmaceutical and biotech companies, academic and research institutions, clinical diagnostic laboratories, government agencies and sectors focusing on environmental, industrial quality and process control. Its products and services are distributed through a variety of channels, including direct sales force, e-commerce platforms and third-party distributors across the Americas, Asia-Pacific and Europe. Headquartered in Waltham, Massachusetts, USA, Thermo Fisher continues to expand its presence.
In May 2023, Thermo Fisher Scientific Inc. (USA) and the National Research and Innovation Agency of Indonesia (BRIN) entered into a Memorandum of Understanding (MOU) aimed at facilitating and enhancing Indonesia's national research and innovation infrastructure and capabilities.